ERAS announces a new acquisition

ERAS acquires the pharmaceutical and chemical branches of SNC LAVALIN SAS France thus consolidating its expertise in life sciences.

The company ERAS announces the acquisition of the engineering and project management process industry activities of the pharmaceutical and chemical sectors of SNC Lavalin SAS France. The SNC Lavalin group is recognized as one of the largest engineering and construction groups worldwide.

This operation involves around fifty people, who will now join the ERAS agency in the 7th district of Lyon. Made possible after a strategic repositioning of the SNC Lavalin group in France, this integration takes the number of acquisitions carried out by the ERAS group in nearly 20 years up to 12, and went into effect on the 1st September. It will allow ERAS to accelerate its developmental strategy and expand its customer base in the process industry, particularly in the life sciences, but also to corroborate its position in the chemical sector.

“We want to become more aggressive in our markets, notably on a global scale, by developing our expertise and yet maintaining a sense of proximity and reactivity that are two of our key strengths” confirms Yves Poivey, President of ERAS. “This new acquisition brings us undeniable knowledge in an area that we want to expand in: the pharmaceutical industry.”

 

Strengthened expertise in the Life Sciences

Through this acquisition, ERAS has strengthened its life sciences centre of excellence, which was already made up of technical experts, supervised by project managers dedicated to the activity.

The team of engineers and technicians intervene on standard pharmaceutical industry, biotechnology and cosmetics issues, such as:

  • The processes employed to produce dosage forms (weighing, formulation, conditioning);
  • Air treatment: clean rooms (controlled atmosphere areas) and containment in general;
  • Buildings and sub-contract work specific to these markets;
  • Logistical aspects (flow, storage, controlling temperature and humidity…);
  • R&D laboratories
  • “Supporting” roles related to quality control (sampling, QC laboratories, archiving, etc.);
  • Qualification of systems from conception through to production.

“Up until now, the pharmaceutical sector was more of a national market for us. Thanks to this acquisition, we will not only be able to develop our competences but also open up to new geographical zones, such as Maghreb, where SNC Lavalin SAS France is already present” says Yves Poivey.

 

Corroborated expertise in the chemical sector

The chemical sector has been strategic to ERAS since its creation. This operation, coupled to the integration of CHEMSIS in September 2012, corroborates the position of ERAS in the chemical sector through the arrival of new expertise.

ERAS aims to bring even more added value to their esteemed customers’ services, adapted to projects of all sizes. Its ambition is also to get new clients to trust its teams, as already is the case in the chemical and life science sectors for BASF, Bayer, Dow, Dupont de Nemours, GSK, Novacap, Novartis, Pfizer, Sanofi, Solvay/Rhodia, Syngenta, etc.

 

Key figures

  • ERAS 2013 forecast turnover: 55 million euros.
  • Personnel on 01-09-2013: 500 employees, including 64% executives.
Back to list